



BC Centre for Disease Control
Provincial Health Services Authority

Communicable Diseases and Immunization Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: August 8, 2022

Administrative Circular: 2022:34

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products**

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine SPIKEVAX™ (Moderna) (6 Years of Age and Older)

- Adverse Events: The reported rates of myocarditis and pericarditis have been updated.

Please remove page numbers: 1-5 dated July 22, 2022
Please add new page numbers: 1-5 dated August 8, 2022

COVID-19 Vaccine SPIKEVAX™ (Moderna) (6 months – 5 years of age)

- Doses and Schedule: Content has been added to the footnotes to clarify that if the Pfizer-BioNTech vaccine is unavailable or if Moderna vaccine is requested by the parent/guardian, the age-appropriate Moderna vaccine may be given, provided that informed consent includes that the Pfizer-BioNTech vaccine is preferred for this age group.
- Adverse Events: The reported rates of myocarditis and pericarditis have been updated.

Please remove page numbers: 1-4 dated July 22, 2022
Please add new page numbers: 1-4 dated August 8, 2022

Influenza Vaccines

2022/23 Seasonal Influenza Vaccines

- Influenza pages for the 2022/23 season have been revised.
- The eligibility criteria for publicly funded influenza vaccine are unchanged.

Page 1 of 4

- Revisions to the influenza pages include:
 - The vaccine strains contained in the 2022/23 influenza vaccines.
 - The “Intended Use of Influenza Vaccines” table has been revised to include the vaccines for the 2022/23 publicly funded program. The page has a link to a newly developed Question & Answer document for health care providers related to [Influenza Vaccines for Adults 65 Years of Age and Older](#), which replaces the FLUZONE® HIGHDOSE QUADRIVALENT Influenza Vaccine Question & Answer document.
 - For recipients of a CTLA-4 inhibitor (e.g., ipilimumab) alone or in combination with other checkpoint inhibitors for the treatment of cancer, the interval between influenza vaccine and before starting treatment or after last dose has been revised from 4-6 weeks to 4 weeks. For more specific details, refer to the BC Cancer [Influenza vaccine recommendations](#).
 - FLUMIST® QUADRIVALENT may be offered to those 18-59 years of age who have needle phobia and are unwilling to get another influenza vaccine, provided informed consent includes that QIIV provides better protection against influenza for this age group.
 - A new product page has been added for FLUAD®. This vaccine is publicly funded for those 65 years of age and older residing in the community.

Please remove the following pages:

- 2021/22 Seasonal Influenza Vaccine Eligibility: page 1 dated October 2021
- Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2021
- Intended Use of Influenza Vaccines: page 1 dated August 2021
- FLUMIST® QUADRIVALENT: pages 1-3 dated August 2021
- AFLURIA® TETRA: pages 1 & 2 dated August 2021
- FLULAVAL® TETRA: pages 1 & 2 dated August 2021
- FLUZONE® QUADRIVALENT: pages 1 & 2 dated August 2021
- FLUZONE® HIGH-DOSE QUADRIVALENT: pages 1 & 2 dated September 2021

Please add the following pages:

- 2022/23 Seasonal Influenza Vaccine Eligibility: page 1 dated August 2022
- Safety Issues Applicable to Influenza Vaccines: page 1 dated August 2022
- Intended Use of Influenza Vaccines: page 1 dated August 2022
- FLUAD®: pages 1 & 2 dated August 2022
- FLUMIST® QUADRIVALENT: pages 1-3 dated August 2022
- FLUZONE® QUADRIVALENT: pages 1 & 2 dated August 2022
- FLUZONE® HIGH-DOSE QUADRIVALENT: pages 1 & 2 dated August 2022

Monkeypox Vaccine

Smallpox and Monkeypox Vaccine (Live attenuated, non-replicating): IMVAMUNE®

- How to request the vaccine for release has been removed.
- Doses and Schedules has been updated as follows:
 - Pre-Exposure Prophylaxis has been revised from 2 doses to 1 dose
 - Footnote B has been added to clarify that a 2nd dose is not indicated following a subsequent exposure.
 - Content has been included to indicate individuals who are moderately to severely immunocompromised should be offered 2 doses, 4 weeks apart. Appendix A has been added to further clarify who is considered moderately to severely immunocompromised.
- Storage and Handling has been updated to indicate that the expiry date for vaccine which is stored at -25°C to -15°C needs to be revised to 3 months from the date it is moved from -90°C to -70°C storage.
- Special Considerations has been updated as follows:
 - The administration of Imvamune® for post-exposure prophylaxis should not be delayed in an individual who has recently received another vaccine.
 - Vaccine is not indicated for individuals with laboratory confirmed monkeypox as they are assumed to have acquired immunity from infection.

Please remove page numbers: 1-3 dated July 8, 2022
Please add new page numbers: 1-4 dated August 8, 2022

The [Monkeypox Vaccine Client Information Sheet](#) has been updated to indicate that vaccine recipients may be contacted to participate in safety monitoring for monkeypox vaccine. A link to the CANVAS Monkeypox Vaccine Safety Study has been added.

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated July 29, 2022, and replace with the enclosed updated Title Page and Table of Contents dated August 2022.

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHS Sc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health &
Wellness, PHSA & Deputy Provincial
Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population &
Public Health Division:

Brian Sagar
Senior Director Communicable
Disease, Population and Public Health
Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division